Clinical trials: Advanced and/or Metastatic Solid Tumours
Solid Tumors, Adult
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.
- Trial name
- NCT07396584
- Testing
- HMPL-A580
- Where
- 14 sites in United States, China
- Volunteers
- 186 people
- Sponsor
- Hutchmed
Solid Tumor, Glioblastoma
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid…
- Conditions
- Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT04982926
- Testing
- TAS2940
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Taiho Oncology, Inc.
Breast Cancer
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors will be investigated to determine the dose-limiting toxicity (DLT)…
- Trial name
- NCT05339685
- Testing
- BL-M02D1
- Where
- 10 sites in China
- Volunteers
- 82 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Adult Solid Tumor
Study of LTC004 in Subjects With Advanced Malignant Tumors
This was a multicenter, open, multi-cohort PHASE I study, consisting of 2 phases: Phase Ia (Phase Ia dose escalation) and Phase Ib (Phase Ib multi-cohort expansion).
- Trial name
- NCT05666635
- Testing
- LTC004
- Volunteers
- 368 people
- Sponsor
- Letolab
Solid Tumor
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment, nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M08D1 for…
- Trial name
- NCT06718621
- Testing
- BL-M08D1
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
This is a first-in-human (FIH) phase 1 open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL501 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary anti-tumor…
- Trial name
- NCT05101109
- Testing
- ABL501
- Where
- 4 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- ABL Bio, Inc.
Advanced or Metastatic Solid Tumors
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
A pharmacokinetic study to compare 2 clinical formulations of linifanib and the effect of food on the pharmacokinetics of linifanib.
- Trial name
- NCT01506934
- Testing
- linifanib
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Abbott
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
- Conditions
- Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
- Trial name
- eVOLVE-02 (NCT06535607)
- Testing
- Volrustomig, Cisplatin, Carboplatin
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 257 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
This is a Phase Ib, open-label, multicenter study of HSK41959 tablets in combination with standard therapy in patients with MTAP-deficient advanced solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
- Trial name
- NCT07699757
- Testing
- HSK41959, Sintilimab, Pemetrexed + Cisplatin /Carboplatin
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Solid Tumour, Advanced Solid Malignancies
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
This is Phase I, open-label and dose escalation study to evaluate the safety and tolerability of AZD1480(JAK2 inhibitor) in Asian patients with advanced solid tumors (Part A and C) and in patients with advanced HCC (Part B) in…
- Conditions
- Solid Tumour, Advanced Solid Malignancies, Child-Pugh A to B7 Advanced Hepatocellular Carcinoma, EGFR and/or ROS Mutant NSCLC
- Trial name
- NCT01219543
- Testing
- AZD1480 Daily, AZD1480 BID
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Advanced Cancer
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
The main purpose of this study is to evaluate the safety of the study drug known as Prexasertib (LY2606368) in participants with advanced cancer or cancer that has spread to other parts of the body.
- Trial name
- NCT02778126
- Testing
- [¹⁴C]Prexasertib, Prexasertib
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Solid Tumor
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
This is a first-in-human (FIH) study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-R046 as a single agent and in combination with tislelizumab…
- Trial name
- NCT06487858
- Testing
- BGB-R046, Tislelizumab
- Where
- 8 sites in China
- Volunteers
- 42 people
- Sponsor
- BeOne Medicines
Solid Tumors
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid…
- Trial name
- NCT05644626
- Testing
- BGB-B167, Tislelizumab
- Sponsor
- BeiGene
Breast Cancer, Solid Tumor
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 bispecific…
- Trial name
- NCT07753226
- Testing
- SI-B036
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00016874
- Testing
- cisplatin, paclitaxel, triapine
- Where
- 2 sites in United States
- Sponsor
- Vion Pharmaceuticals
Solid Tumors
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
This study will be conducted in 5 parts (Parts A, B, C, D and E). Monotherapy Treatment: Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Monotherapy dose escalation will be performed in Part A.
- Trial name
- NCT02628574
- Testing
- TRX518 monotherapy, TRX518 with gemcitabine, TRX518 with pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Leap Therapeutics, Inc.
Advanced or Metastatic Solid Tumors
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
This is the first in human study of KK2260. In Part 1a, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors (any cancer…
- Trial name
- NCT06248411
- Testing
- KK2260
- Where
- 14 sites in Japan
- Volunteers
- 189 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Advanced Solid Cancers, Metastatic Cancer
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.
- Trial name
- NCT00886782
- Testing
- Cdc7-inhibitor
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 11 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
A Study of ASP1951 in Subjects With Advanced Solid Tumors
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or…
- Trial name
- NCT03799003
- Testing
- ASP1951, pembrolizumab
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Hepatocellular Carcinoma
SynOV1.1 Intratumoral Injection Study
This is a Phase I, open-label, multicenter study to characterize safety and tolerability, evaluate biodistribution, biological effects and immunogenicity, and evaluate the preliminary clinical efficacy of SynOV1.1 in participants…
- Trial name
- NCT04612504
- Testing
- SynOV1.1
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Syngentech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.